Effects of сramizol on expression of the ApoA1 gene in rats with experimental hyperlipidemia

   
Lizunov A.V.1 , Okunevich I.V.2, Orlov S.V.1, Lebedev A.A.2, Bychkov E.R.3, Piotrovskiy L.B.2, Shabanov P.D.3

1. Institute of Experimental Medicine, St. Petersburg, Russia; St Petersburg University, St. Petersburg, Russia
2. Institute of Experimental Medicine, St. Petersburg, Russia
3. Institute of Experimental Medicine, St. Petersburg, Russia; Kirov Military Medical Academy, St. Petersburg, Russia
Section: Experimental Study
DOI: 10.18097/PBMC20196505403      PubMed Id: 31666413
Year: 2019  Volume: 65  Issue: 5  Pages: 403-406
An imidazole derivative cramizol, has lipid-lowering and anti-atherogenic effects. Cramizol reduces blood levels of cholesterol and triglycerides, and also reduces the atherogenic index in animals with acute hyperlipidemia induced by Triton WR-1339. Cramizol and the lipid-lowering drug fenofibrate exhibited similar effectiveness as hypolipidemic agents. Cramizol also restores the expression of the Apoa1 gene in rats with experimentally induced hyperlipidemia to normal values. This may be a basis of its hypolipidemic and anti-atherogenic action.
Download PDF:
Keywords: cramizol, experimental hyperlipidemia, Triton WR-1339, cholesterol, triglycerides, apolipoprotein A1
Citation:

Lizunov, A. V., Okunevich, I. V., Orlov, S. V., Lebedev, A. A., Bychkov, E. R., Piotrovskiy, L. B., Shabanov, P. D. (2019). Effects of сramizol on expression of the ApoA1 gene in rats with experimental hyperlipidemia. Biomeditsinskaya khimiya, 65(5), 403-406.
References  
 2019 (vol 65)
 2018 (vol 64)
 2017 (vol 63)
 2016 (vol 62)
 2015 (vol 61)
 2014 (vol 60)
 2013 (vol 59)
 2012 (vol 58)
 2011 (vol 57)
 2010 (vol 56)
 2009 (vol 55)
 2008 (vol 54)
 2007 (vol 53)
 2006 (vol 52)
 2005 (vol 51)
 2004 (vol 50)
 2003 (vol 49)